Aurobindo Pharma (BOM:524804) 5-Year EBITDA Growth Rate : 3.00% (As of Dec. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Aurobindo Pharma 5-Year EBITDA Growth Rate?

Aurobindo Pharma's EBITDA per Share for the three months ended in Dec. 2024 was ₹29.90.

During the past 12 months, Aurobindo Pharma's average EBITDA Per Share Growth Rate was 23.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -10.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 3.00% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 10.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aurobindo Pharma was 233.90% per year. The lowest was -35.40% per year. And the median was 12.70% per year.

Competitive Comparison of Aurobindo Pharma's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aurobindo Pharma's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's 5-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Aurobindo Pharma 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Aurobindo Pharma (BOM:524804) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Aurobindo Pharma 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurobindo Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (BOM:524804) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

AUROPHARMA:India

Address

Plot No. 1, Survey No. 83/1, Galaxy, Floors 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500032

Website

https://www.aurobindo.com

Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.

Aurobindo Pharma Headlines

No Headlines